Medication info
DapaGlynSM Sustained Release Tablet 5/50/1000 mg (Dapagliflozin, Sitagliptin, Metformin)

DapaGlynSM Sustained Release Tablet 5/50/1000 mg (Dapagliflozin, Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletDapagliflozin Propanediol Hydrate›6.15mg / 1 tabletSitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Kyungdong Pharmaceutical Co., Ltd.
Appearance
Light yellow, oval, biconvex, sustained-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500710 · Approved 2025.03.27 · Insurance code 648105220

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is 10 mg of dapagliflozin and 100 mg of sitagliptin. The dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs to be adjusted, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 5/50/1000 mg extended-release tablets should take 2 tablets together once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be 10 mg dapagliflozin, 100 mg sitagliptin, and the current dose of metformin hydrochloride or a therapeutically equivalent dose. For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the same as the previous doses of each component. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from another antihyperglycemic agent. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Special populations Patients with renal impairment As the efficacy and safety of this medicine depend on renal function and dosage adjustment according to renal function is required, it is recommended that renal function be assessed before treatment and periodically thereafter. No dose adjustment is necessary for patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other symptoms that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months.

Ingredients

Manufacturer
Kyungdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with dapagliflozin, sitagliptin, and metformin to help manage blood sugar levels in patients with type 2 diabetes. It is used for patients who are also following dietary and exercise regimens, and helps enhance the effectiveness of blood sugar control. This contributes to maintaining stable blood sugar levels and preventing complications associated with diabetes. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is 10 mg of dapagliflozin and 100 mg of sitagliptin. The dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs to be adjusted, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 5/50/1000 mg extended-release tablets should take 2 tablets together once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be 10 mg dapagliflozin, 100 mg sitagliptin, and the current dose of metformin hydrochloride or a therapeutically equivalent dose. For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the same as the previous doses of each component. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from another antihyperglycemic agent. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Special populations Patients with renal impairment As the efficacy and safety of this medicine depend on renal function and dosage adjustment according to renal function is required, it is recommended that renal function be assessed before treatment and periodically thereafter. No dose adjustment is necessary for patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other symptoms that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months.

Precautions

This medication contains the ingredients sitagliptin, dapagliflozin, and metformin, which are used for diabetes treatment. Sitagliptin can rarely cause severe allergic reactions, so if you experience symptoms such as skin rash, difficulty breathing, or swelling of the face or neck, you should immediately stop taking this medication and consult a doctor. Additionally, serious side effects such as acute pancreatitis, which is inflammation of the pancreas, have been reported. Therefore, if you experience symptoms such as abdominal pain, vomiting, or nausea, you should visit a hospital immediately. Dapagliflozin can reduce the body's fluid volume and lower blood pressure, so patients at risk for dehydration or hypotension should use it with caution. Patients with decreased kidney function should take it under regular monitoring. Metformin can rarely cause lactic acidosis, which can be life-threatening, so if you experience unusual symptoms such as shortness of breath, muscle pain, fatigue, or abdominal pain, you should notify medical staff immediately. This medication should not be administered to patients with severely impaired kidney function, acute heart disease, severe liver disease, or severe infections. Also, if you are scheduled for surgery or will be undergoing tests that involve contrast agents, you should temporarily stop taking this medication and only resume after confirming that kidney function is normal post-surgery. When used in combination with multiple medications for blood sugar control, there is a risk of hypoglycemia, so symptoms of hypoglycemia such as dizziness, cold sweats, and severe fatigue should be carefully monitored. Genital infections or urinary tract infections may occur, so if related symptoms appear, immediate treatment is necessary, especially if there is a history of such infections. It is important to regularly check kidney function and liver function while taking this medication, and consult medical staff immediately if abnormal symptoms arise.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
Show 102 more
  • urinary tract infection
  • fungal infection
  • perineal necrosis
  • decreased fluid volume
  • thirst
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbago
  • dysuria
  • polyuria
  • nocturia
  • interstitial nephritis
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased serum creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • rash
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • gastroesophageal reflux disease
  • upper abdominal pain
  • diverticulosis
  • intestinal perforation
  • chronic pancreatitis
  • hyperglycemia
  • paresthesia
  • cerebral infarction
  • nerve compression
  • sinusitis
  • diverticulitis
  • pelvic inflammatory disease
  • pneumonia
  • pulmonary tuberculosis
  • asthenia
  • pain
  • ligament sprain
  • road traffic accident
  • drug overdose
  • ankle fracture
  • hand fracture
  • ileal fracture
  • meniscus injury
  • thoracic spine fracture
  • tibial fracture
  • keratitis
  • chronic obstructive pulmonary disease
  • hemoptysis
  • cerebral hemorrhage
  • peripheral artery occlusion
  • angina pectoris
  • myocardial infarction
  • choledocholithiasis
  • cholangitis
  • alcoholic cirrhosis
  • depression
  • suicide attempt
  • gastric adenocarcinoma
  • food allergy
  • erythrocytosis
  • dyspepsia
  • nausea
  • diarrhea
  • vomiting
  • urinary retention
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • decreased appetite
  • headache
  • nasopharyngitis
  • chest pain
  • hunger
  • vaginal discharge
  • pruritus
  • urticaria
  • cold sweat
  • arthralgia
  • musculoskeletal pain
  • limb pain
  • muscle weakness
  • myalgia
  • osteoarthritis
  • ligament strain
  • diabetic retinopathy
  • cough
  • dyspnea
  • orthostatic hypotension
  • palpitations
  • insomnia
  • fatty liver
  • gallbladder polyp
  • tinnitus
  • taste disturbance
  • erythema
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is best stored at room temperature between 1°C and 30°C, avoiding extremely hot or cold places.

Appearance and packaging

Appearance

Light yellow, oval, biconvex, sustained-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.